X

Trial Profile

Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tenofovir alafenamide (Primary)
Indications Hepatitis B
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

14 Nov 2023 Interim results of 48 week safety and efficacy of tenofovir alafenamide in hepatitis B patients were presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
20 May 2023 Status changed from recruiting to active, no longer recruiting.
30 Jun 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com